Literature DB >> 11774282

Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth.

Takayuki Furumatsu1, Keiichiro Nishida, Akira Kawai, Masayoshi Namba, Hajime Inoue, Yoshifumi Ninomiya.   

Abstract

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are well-known factors that induce neovascularization in many tumors. The molecular mechanisms that regulate tumor angiogenesis in human chondrosarcoma are not clear. We assessed in this work the angiogenic activities of a human chondrosarcoma cell line (OUMS-27) in vivo and determined the efficacies of angiogenic factors derived from OUMS-27 cells on human umbilical vein endothelial cells (HUVECs) in vitro. Tumor xenografts induced an increase in the formation of neovessels, but the distributions of Ki-67 antigen, VEGF and bFGF were unaffected. We also demonstrated that OUMS-27 cells secreted VEGF(165) into the culture medium and that it was the maximal angiogenic factor to stimulate endothelial proliferation and migration in chondrosarcoma. Anti-VEGF antibodies induced an approximately 70% inhibition of these responses of HUVECs, but did not have any effect on OUMS-27 cells. Anti-bFGF antibodies suppressed not only the activities of HUVECs but also the growth of tumor cells in vitro. We indicate that angiogenesis is principally elicited by VEGF(165) and that tumorigenesis is mainly regulated by bFGF stored in the extracellular matrix of OUMS-27 cells. The present study may offer the availability of combination therapies for inhibition of VEGF and bFGF action on vascular endothelial cells and chondrosarcoma cells, respectively. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774282     DOI: 10.1002/ijc.1607

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.

Authors:  R Akhavan-Sigari; M R Gaab; V Rohde; A Brandis; H Tezval; M Abili; K von Eckardstein; H Ostertag
Journal:  Neurosurg Rev       Date:  2013-09-03       Impact factor: 3.042

2.  The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Authors:  Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P Dinney; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

Review 3.  Systemic Therapy for Chondrosarcoma.

Authors:  Adam Rock; Sana Ali; Warren A Chow
Journal:  Curr Treat Options Oncol       Date:  2022-02-21

Review 4.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

5.  Synthetic disulfide-bridged cyclic peptides mimic the anti-angiogenic actions of chondromodulin-I.

Authors:  Shigenori Miura; Jun Kondo; Toru Kawakami; Chisa Shukunami; Saburo Aimoto; Hideyuki Tanaka; Yuji Hiraki
Journal:  Cancer Sci       Date:  2012-04-27       Impact factor: 6.716

6.  Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors.

Authors:  Christopher A Hamm; Jeff W Stevens; Hehuang Xie; Elio F Vanin; Jose A Morcuende; Hakeem Abdulkawy; Elisabeth A Seftor; Simone T Sredni; Jared M Bischof; Deli Wang; Sergey Malchenko; Maria de Fatima Bonaldo; Thomas L Casavant; Mary J C Hendrix; Marcelo B Soares
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

7.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

Authors:  Francisco Fontes Cintra; Mauricio Etchebehere; José Carlos Barbi Gonçalves; Alejandro Enzo Cassone; Eliane Maria Ingrid Amstalden
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

Authors:  E David; F Blanchard; M F Heymann; G De Pinieux; F Gouin; F Rédini; D Heymann
Journal:  Sarcoma       Date:  2011-05-22

Review 9.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Chondrosarcoma and peroxisome proliferator-activated receptor.

Authors:  K Nishida; T Kunisada; Z N Shen; Y Kadota; K Hashizume; T Ozaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.